Company DMK Pharmaceuticals Corporation

DMKP.Q

US00547W3079

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:47:05 29/06/2024 am IST			5-day change	1st Jan Change
0.0293 ^USD	0.00%		-17.93%	-95.82%

20/06	ZMI Pharma, Inc acquired Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation.	CI
14/06	First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation	CI

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Companyâs commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Companyâs lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Companyâs other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinsonâs disease.

Number of employees: 12

USD in Million	2021	Weight	2022	Weight	Delta
Drug Development and Commercialization 100.0 %	2	100.0 %	5	100.0 %	+115.34%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	2	100.0 %	5	100.0 %	+115.34%

Managers	Title	Age	Since
Ebrahim Versi CEO	Chief Executive Officer	71	25/23/25
Seth Cohen DFI	Director of Finance/CFO	42	16/23/16
Robert H. Uhl IRC	Investor Relations Contact	-	-
John Dorbin LAW	General Counsel	53	19/23/19
Thomas H. Moll PRN	Corporate Officer/Principal	58	22/09/22

Members of the board	Title	Age	Since
Howard Birndorf BRD	Director/Board Member	74	26/19/26
Ebrahim Versi CEO	Chief Executive Officer	71	25/23/25
Vickie Reed BRD	Director/Board Member	62	24/22/24
Jannine Versi BRD	Director/Board Member	38	25/23/25
Meera Desai BRD	Director/Board Member	45	01/21/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,109,520	9,167,003 ( 90.68 %)	7,470 ( 0.0739 %)	90.68 %

Name	Equities	%	Valuation
Versi Group LLC 8.972 %	906,394	8.972 %	27 192 $
Dennis J. Carlo 0.0979 %	9,892	0.0979 %	297 $
Ebrahim Versi 0.0866 %	8,745	0.0866 %	262 $
David Marguglio 0.0339 %	3,425	0.0339 %	103 $
Ronald B. Moss 0.0285 %	2,884	0.0285 %	87 $
Jannine Versi 0.0246 %	2,481	0.0246 %	74 $
David Benedicto 0.005633 %	569	0.005633 %	17 $
Harbour Investments, Inc. 0.001812 %	183	0.001812 %	5 $
Atomic Clock Partners, Inc. 0.000713 %	72	0.000713 %	2 $
Clear Point Advisors, Inc. 0.000525 %	53	0.000525 %	2 $

Name	Equities	%	Valuation
Lincoln Park Capital LLC 100.00 %	3,000	100.00 %	90 $

Name	Equities	%	Valuation
Jannine Versi -	1,941	-	58 $
Versi Group LLC -	1,212	-	36 $

DMK Pharmaceuticals Corp.

11682 El Camino Real Suite 300

92130, San Diego

+858 997 2400

http://www.adamispharmaceuticals.com

address DMK Pharmaceuticals Corporation(DMKP.Q)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
DMK PHARMACEUTICALS CORPORATION	-95.82%	296K
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals